1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc.

TMO.NE
Thermo Fisher Scientific Inc.CN flagCBOE CA
18.26
CAD
-0.10
- -
251.90BMarket Cap
Thermo Fisher Scientific Inc.
TMO.NE
(CBOE CA)

Recent

price

18.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.7
0.83
0.94
0.99
1.16
1.16
1.26
1.44
1.65
1.74
2.22
2.71
3.12
3.02
3.06
3.22
3.28
Revenue per Share
0.07
0.1
0.09
0.1
0.13
0.13
0.14
0.15
0.2
0.25
0.44
0.53
0.48
0.42
0.45
0.48
0.5
Basic EPS, GAAP
0.08
0.1
0.13
0.13
0.15
0.17
0.19
0.24
0.26
0.28
0.47
0.47
0.48
0.49
0.52
0.45
0.49
Free Cash Flow per Basic Share
- -
- -
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.04
0.04
0.05
0.05
Dividend per Share
0.39
0.51
0.61
0.69
0.74
0.86
0.99
1.13
1.3
1.53
1.96
2.48
2.94
3.37
3.82
4.31
4.43
Book Value per Share
0.03
-0.34
-0.36
-0.21
-0.85
-0.7
-0.95
-1.14
-0.86
-0.68
-0.29
-1.46
-1.01
-0.98
-0.84
-0.84
-1.62
Tangible Book Value per Share
14,808
13,982
13,358
13,230
14,621
14,640
14,496
14,504
14,761
14,687
14,540
14,467
14,393
14,173
14,026
13,843
13,782
Basic Weighted Avg Shares
10,393
11,559
12,510
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
45,196
Sales/Revenue/Turnover
12.01
11.66
12.5
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.16
Operating Margin (%)
746
860
984
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,811
Depreciation Expense
1,036
1,330
1,178
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
6,848
Net Income, GAAP
9.34
9.66
0.87
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.03
Effective Tax Rate (%)
9.96
11.51
9.42
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.15
Profit Margin (%)
2,425
1,709
2,742
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
7,695
Working Capital
2,031
5,755
7,031
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
40,071
LT Debt
15,361
15,038
15,465
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
52,061
Total Equity
6.44
6.16
6.96
6.57
5.54
- -
- -
6.63
7.44
8.1
13.47
13.57
10.05
8.73
8.62
8.65
8.54
Return on Invested Capital (%)
14.95
13.48
9.65
8.77
10.36
- -
- -
8.1
9.38
10.99
15.15
13.51
10.28
9.19
9.05
8.69
8.47
Return on Capital (%)
19.61
20.6
15.46
14.78
19
16.9
15.04
14.5
16.57
17.75
24.96
23.98
17.77
13.3
12.5
11.85
11.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3,823
3,533
3,090
LT Borrowings
31,857
35,852
40,071
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
376
376
372
Market Capitalization
176,710
212,478
176,557

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
22,295
28,707
22,316
Cash, Cash Equivalents & STI
3,546
10,105
3,256
Accounts Receivable, Net
8,911
8,900
9,204
Inventories
5,745
5,425
5,496
Total Current Liabilities
14,888
15,189
14,621
Payables & Accruals
8,213
8,946
8,603
ST Debt
3,823
3,533
3,090
Deferred Revenue
2,852
2,710
2,928

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.11
0.12
0.13
0.45
2025
0.11
0.12
- -
0.14
0.48
2026
0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
- -
0.01
0.05
2026
0.01
- -
- -
- -
- -
Similar Companies
CareDx, Inc (CDNA)
RadNet, Inc. (RDNT)
Optigenex Inc. (OPGX)
Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
HTG Molecular Diagnostics, Inc. (HTGMQ)
StageZero Life Sciences Ltd. (SZLS.TO)
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, reagents, consumables, software and services for research, analysis, discovery, diagnostics and bioprocessing applications; the company serves pharmaceutical and biotech firms, hospitals, clinical diagnostic laboratories, universities, research institutions, government agencies and industrial sectors with products including mass spectrometry systems, chromatography instruments, spectroscopy equipment, laboratory information management systems, biological reagents, diagnostic assays, cell culture media such as Gibco brands, antibodies and protein purification tools from Invitrogen, fine chemicals, immunodiagnostic tests and biomanufacturing solutions. Headquartered in Waltham, Massachusetts, and formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International Inc., Thermo Fisher operates globally across North America, Europe, Asia-Pacific and other regions through brands such as Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon pharmaceutical services and PPD clinical research. The company maintains four primary segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products, and Biopharma Services, targeting scientific research, healthcare, environmental monitoring and industrial quality control markets. Recent developments include a definitive agreement in February 2025 to acquire Solventum Corp.'s Purification and Filtration business for $4.1 billion to enhance bioprocessing capabilities, the expansion of sterile fill-finish capacity through the acquisition of Sanofi's Ridgefield, New Jersey site in 2025 as part of a deepened strategic partnership, and bioprocessing investments in Asia with a new Bioprocess Design Center in Hyderabad, India, alongside expansions in Incheon, Korea, and Singapore in late 2025.